THE Therapeutic Goods Administration has posted broadened indications for two prescription medicines this month.
Merck Sharp & Dohme's Keytruda (pembrolizumab rch) is now also indicated for relapsed or refractory classical Hodgkin Lymphoma (cHL) under specific conditions.
Novartis' asthma therapy Ultibro Breezhaler 110/50 (indacaterol as maleate/glycopyrronium as bromide) is now also indicated for exacerbations of COPD in patients with a history of exacerbations.
These extended uses took effect on 07 and 06 Sep respectively.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 17